Scholarlink

Background <p>Sleeve gastrectomy (SG) induces substantial metabolic improvement in patients with type 2 diabetes (T2DM), but glycemic remission remains heterogeneous. We evaluated metabolic, continuous glucose monitoring (CGM), and quality-of-life (QoL) outcomes after SG according to remission status.</p> Methods <p>Prospective observational study of patients with severe obesity and T2DM undergoing SG that were evaluated preoperatively and at 12 months. Patients were analyzed in T2DM remission (RG) and persistent diabetes (PG) groups.</p> Results <p>RG included 15, while PG 18 patients. Weight loss and excess BMI loss were comparable between groups. RG demonstrated greater improvement in fasting glucose and HOMA-IR at follow-up, while HOMA-B decreased significantly in RG but increased in PG, suggesting divergent β-cell adaptation. CGM showed significant postoperative improvement in both groups, with consistently lower mean glucose and fewer hyperglycemic readings in RG. Hypoglycemia indices increased in both groups. QoL improved substantially across BAROS and SF-36 domains, with more pronounced physical improvements; between-group differences in QoL were modest despite distinct metabolic trajectories.</p> Conclusions <p>SG provided meaningful metabolic and quality-of-life benefits, particularly in patients achieving remission, suggesting potential benefits of earlier surgical referral before advanced β-cell deterioration limits the potential for metabolic recovery, and highlighting the value of CGM for individualized postoperative de-escalation of therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic heterogeneity after laparoscopic sleeve gastrectomy in type 2 diabetes mellitus patients with severe obesity: insights from continuous glucose monitoring, glycemic profiles and quality of life

  • 期刊论文

  • 发表日期：

    2026年2月12日

查看全文
  • Michał Wysocki,
  • Piotr Małczak,
  • Anna Rajtar,
  • Katarzyna Major,
  • Piotr Major

摘要

Background

Sleeve gastrectomy (SG) induces substantial metabolic improvement in patients with type 2 diabetes (T2DM), but glycemic remission remains heterogeneous. We evaluated metabolic, continuous glucose monitoring (CGM), and quality-of-life (QoL) outcomes after SG according to remission status.

Methods

Prospective observational study of patients with severe obesity and T2DM undergoing SG that were evaluated preoperatively and at 12 months. Patients were analyzed in T2DM remission (RG) and persistent diabetes (PG) groups.

Results

RG included 15, while PG 18 patients. Weight loss and excess BMI loss were comparable between groups. RG demonstrated greater improvement in fasting glucose and HOMA-IR at follow-up, while HOMA-B decreased significantly in RG but increased in PG, suggesting divergent β-cell adaptation. CGM showed significant postoperative improvement in both groups, with consistently lower mean glucose and fewer hyperglycemic readings in RG. Hypoglycemia indices increased in both groups. QoL improved substantially across BAROS and SF-36 domains, with more pronounced physical improvements; between-group differences in QoL were modest despite distinct metabolic trajectories.

Conclusions

SG provided meaningful metabolic and quality-of-life benefits, particularly in patients achieving remission, suggesting potential benefits of earlier surgical referral before advanced β-cell deterioration limits the potential for metabolic recovery, and highlighting the value of CGM for individualized postoperative de-escalation of therapy.